Search Results

Receptor-Selective Fluorescent Probes and Applications in Single-Molecule Microscopy of Wild-Type Receptors Dr We’re thrilled to announce our upcoming courses with Dr. Terry Kenakin! Courses Schedule and Benefits Every Thursday at 10 am EST Online Lectures 1:1 meeting with Dr. Cryo-Electron Microscopy Postdoctoral Research Associate Senior Scientist - Discovery Biotherapeutics Join Dr

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Hoare's workshop for individuals who live and work in developing countries. Check our conversation with Dr. Sam Hoare about this hands-on workshop HERE ⬇⬇⬇ Dr. Dr.

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between Hoare, according to his availability Access to the cohort’s Dr. Hoare and your classmates Access to the course materials and recordings once the course is completed Hoare and Dr. GPCR Complementary one-year Dr. Hoare's workshop for individuals who live and work in developing countries.

Episode 85 of the Dr. GPCR podcast is here! 🎧Hear Dr. Watch the full video with a paid Dr.

November 2021 Dr. Kevin Pfleger and Dr. "Congratulations to Perkins Professor Kevin Pfleger and Dr Elizabeth Johnstone who were awarded one of

🎙️ Episode 87 of the @DrGPCR podcast with Dr. Bianca Plouffe is available!

📢 Did you know that this 3rd Edition of the Dr.

☕ We are excited to announce our rescheduled Dr. GPCR Virtual Cafe session with Dr.

the kinetic factors that enhance in vivo efficacy beyond traditional potency metrics, as presented by Dr Dr. That's exactly what Dr. Dr. Submit your paper today to secure your work in Volume II ➤ Why Dr.

🌟The Dr. GPCR event of the year is the 3rd edition of the Summit. Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers. Become a Dr. GPCR Ecosystem site member to attend the Summit, it’s free!

⚠️Mark your calendar for the Dr. GPCR Summit 2022 held between Oct. 10 - 16, it's FREE!

. 🔍 This Week in Dr. This week, Dr. Featured Talk: Dr. Terry Kenakin on The Kinetics of Allostery . Secure your seat today ➤ Why Dr. Read the Premium edition here ➤ What our members say 🗣️ "Dr.

📅 Our FREE Dr. GPCR Summit 2022 is less than a month away!

Join Dr. Here’s who we've talked to so far: 🎥 Check out the interview with Dr. . 🌐 Why Dr. GPCR Is in This Conversation At Dr.   📚 Terry’s Corner — The Only On-Demand Pharmacology Hub with Dr. Kenakin Himself If you’re part of the Dr.

July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross Bathgate Read more at the source #DrGPCR #GPCR #IndustryNews

A Broader Lens: Dr. GPCR As the co-founder of Dr.

June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic

Tomorrow is the day for another Dr. GPCR Virtual Cafe. This time with none other than Dr. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Dr. Register and join your colleagues in September ➤ Why Dr. GPCR Premium Membership Gives You an Edge In a world filled with noise, Dr. 👉 Access this week’s full Premium Edition here ➤ Hear What Our Members Are Saying “The content had enough ” - DrGPCR University Course Attendee Get a competitive advantage—Join Dr.

November 2021 Read more at the source #DrGPCR #GPCR #IndustryNews

Excited to hear Dr. Register here (FREE) https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe #drgpcr #gpcr #virtualcafe

Excited to hear Dr. automated micro-plate-based methods for quantifying #GPCR activation. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Come attend this month's virtual café talk to see the awesome work of Dr. Register here (FREE) https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

November 2021 "So proud and grateful to receive honorary doctorate yesterday from Karolinska Institute and celebrate with my family in Stockholm." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

Be sure to signup for the next Virtual Cafe of Dr. GPCR on the 24th of June! This time, the GPCRdb team ( Dr. David Gloriam , Dr. Reserve your spot for free at: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #GPCR #GPCRs #DrGPCR

Join us for a fantastic introduction to GPCRdb with Dr. David Gloriam and Dr. Albert Kooistra. Register today: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Join us for the first virtual cafe talk to hear about the amazing work that Dr. Brian Arey is doing. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

September 2022 "Morphine, the most widely used analgesic, relieves severe pain by activating the μ-opioid receptor (MOR), whereas naloxone, with only slight structural changes compared to morphine, exhibits inhibitory effect, and is used to treat opioid abuse. The mechanism by which the MOR distinguishes between the two is unclear. Molecular dynamics (MD) simulations on a 1-μs time scale and metadynamics-enhanced conformational sampling are used here to determine the different interactions of these two ligands with MOR: morphine adjusted its pose by continuously flipping deeper into the pocket, whereas naloxone failed to penetrate deeper because its allyl group conflicts with several residues of MOR. The endogenous peptide ligand endomorphin-1 (EM-1) underwent almost no significant conformational changes during the MD simulations. To validate these processes, we employed GIRK4S143T, a MOR-activated Gβγ-protein effector, in combination with mutagenesis and electrophysiological recordings. We verified the role of some key residues in the dynamic recognition of naloxone and morphine and identified the key residue I322, which leads to differential recognition of morphine and naloxone while assisting EM-1 in activating MOR. Reducing the side chain size of I322 (MORI322A) transformed naloxone from an inhibitor directly into an agonist of MOR, and I322A also significantly attenuated the potency of MOR on EM-1, confirming that binding deep in the pocket is critical for the agonistic effect of MOR. This finding reveals a dynamic mechanism for the response of MOR to different ligands and provides a basis for the discovery of new ligands for MOR at the atomic level." Read more at the source #DrGPCR #GPCR #IndustryNews